Aim immunotech enters into pancreatic cancer clinical research agreements with astrazeneca and erasmus medical center

Research collaboration will evaluate the potential of aim's ampligen® (rintatolimod) in combination with astrazeneca's imfinzi (durvalumab) for the treatment of pancreatic cancer research collaboration will evaluate the potential of aim's ampligen® (rintatolimod) in combination with astrazeneca's imfinzi (durvalumab) for the treatment of pancreatic cancer
AIM Ratings Summary
AIM Quant Ranking